Group 1 - The company, Chudi Holdings, announced a plan to issue up to 200 million new shares at a price of HKD 0.063 per share, representing a discount of approximately 10% to the closing price on the announcement date [1] - This share placement will result in an increase of approximately 14.29% in the enlarged share capital of the company [1] - The estimated net proceeds from this placement are approximately HKD 12.1 million, which will be used for the company's general working capital [1]

Core Viewpoint - The company, Geely Pharmaceutical, announced a placement and subscription agreement to sell 52,400,000 shares at a price of HKD 16.45 per share, representing a discount of approximately 9.9% from the last closing price of HKD 18.26 on August 18, 2023 [1] Group 1 - The net proceeds from the subscription are expected to be approximately HKD 467.69 million after deducting commissions and estimated expenses [1] - Approximately 90% of the net proceeds is intended for the clinical trial development of subcutaneous and oral peptide candidates related to obesity [1] - About 10% of the net proceeds is suggested to be used for working capital and other general corporate purposes [1]

Core Viewpoint - The company, Qianxin Biotechnology-B (02509.HK), has announced a placement agreement to issue 5 million shares at a price of HKD 20.0 per share, which represents a discount of approximately 10.95% from the market price on August 15 [1][2] Group 1 - The placement shares represent approximately 2.25% of the total issued shares as of the announcement date and about 2.20% of the total issued shares after the placement [1] - The placement is being conducted by CICC as the placement agent, with the sole subscriber being TruMed Health Innovation Fund LP, a Cayman Islands registered exempt limited partnership focused on healthcare stocks [1] - The expected total proceeds from the placement are approximately HKD 100 million, with a net amount of about HKD 99 million after expenses [2] Group 2 - Approximately 60% of the net proceeds will be used to repay existing interest-bearing bank loans, which have increased due to additional borrowing for R&D expenses, thereby improving the company's financial position [2] - About 30% of the net proceeds will be allocated for the development of new product pipelines, including QX027N, QX031N, and QX035N [2] - The remaining 10% of the net proceeds will be used for working capital and other corporate purposes [2]

Core Viewpoint - Chuanghui Jewelry (08537) has successfully completed a placement of 60 million shares at a price of HKD 0.144 per share, raising approximately HKD 8.3 million for operational and general corporate purposes [1] Group 1 - The placement was completed on August 15, 2025, and involved at least six subscribers [1] - The net proceeds from the placement will be used for the group's operational funding and general corporate purposes, including employee costs, rent, procurement, and other administrative expenses [1] - The company anticipates utilizing the proceeds by the end of 2026 [1]

Core Viewpoint - Company completed the placement agreement conditions and successfully placed 9.23 million shares at a price of HKD 17.01 per share, raising approximately HKD 157 million in total proceeds [1] Fund Allocation - Approximately 60% of the net proceeds from the placement, around HKD 93 million, will be used for the research and commercialization of existing pipelines [1] - About 30% of the net proceeds, approximately HKD 46.5 million, will be allocated to enhance internal research capabilities and expand the product portfolio [1] - The remaining 10% of the net proceeds, around HKD 15.5 million, will be utilized for working capital and general corporate purposes [1]

Group 1 - The core point of the article is that China Health Technology (01069) has completed a placement agreement, issuing 17 million shares at a price of HKD 0.28 per share, which represents approximately 16.52% of the company's enlarged issued share capital after the placement [1] Group 2 - As of August 1, the shareholders of China Health Technology deposited shares worth HKD 6.46 million into Changli Securities, accounting for 16.52% of the total [1] - The placement was completed on August 1, 2025, with all conditions of the placement agreement met [1]

Group 1 - The core point of the article is that Southern Manganese (01091) has successfully completed a placement agreement, with a total of 823 million shares being placed at a price of HKD 0.224 per share, which represents approximately 16.67% of the enlarged issued share capital after the placement [1] - On August 1, shareholders of Southern Manganese deposited stocks into Cinda Securities, with a market value of HKD 263 million, accounting for 16.67% [1] - The placement agreement conditions have been fulfilled and will be implemented on July 28, 2025 [1]

Core Viewpoint - WuXi AppTec (603259.SH) announced a plan to issue new H-shares based on the general authorization approved by its board, aiming to raise approximately HKD 7.65 billion for global expansion and operational funding [1][2][3] Group 1: Stock Performance - WuXi AppTec's A-shares closed at CNY 93.00, down 3.40%, while its H-shares closed at HKD 101.70, down 3.79% [1] - The previous day's closing prices were CNY 96.27 for A-shares and HKD 105.70 for H-shares, reflecting declines of 2.61% and 5.63% respectively [1] Group 2: Share Issuance Details - The proposed issuance will not exceed 20% of the currently issued H-shares, amounting to a maximum of 76,336,682 H-shares after accounting for necessary reserves due to convertible bond adjustments [2] - The planned placement will involve 73,800,000 H-shares, subject to adjustments by the Hong Kong Stock Exchange [2] Group 3: Pricing and Fund Utilization - The placement price is set at HKD 104.27 per share, representing a 6.9% discount to the previous closing price of HKD 112 [3] - Approximately 90% of the net proceeds, estimated at HKD 7.65 billion after expenses, will be allocated for global expansion and capacity building, while the remaining 10% will support general operational funding [3]

Core Viewpoint - The article discusses the transfer of shares of Innovent Biologics (09939) from Futu Securities International Hong Kong to BOC International Securities, with a total market value of HKD 124 million, representing 11.04% of the shares [1] Group 1: Share Transfer and Agreement - On July 31, shareholders of Innovent Biologics transferred shares valued at HKD 124 million to BOC International Securities, accounting for 11.04% of the total shares [1] - Innovent Biologics announced an agreement with Dr. Tong Youzhi and the seller (KT International Investment Limited) to sell 20.673 million shares at a price of HKD 2.08 per share, which is approximately 4.62% of the company's issued share capital [1] Group 2: Fundraising Purpose - The placement and subscription are aimed at supplementing the long-term funding for the group's general business and growth strategy [1] - The net proceeds from the subscription are estimated to be approximately HKD 40.34 million after deducting related expenses, which will be used for general working capital and business operations [1]

Group 1 - WuXi AppTec (02359) announced a placement agreement with placement agents to issue 73.8 million new H-shares at a price of HKD 104.27 per share, representing approximately 16.01% of the enlarged issued H-shares and 2.51% of the total issued shares post-placement [2] - The placement price reflects a discount of about 6.90% compared to the last trading price of HKD 112.00 per share on July 30, 2025 [2] - The net proceeds from the placement are expected to be approximately HKD 7.65 billion, with about 90% allocated for accelerating global expansion and capacity building, and about 10% for general corporate purposes [2]